{"id":21949,"date":"2023-02-20T23:38:00","date_gmt":"2023-02-20T15:38:00","guid":{"rendered":"https:\/\/flcube.com\/?p=21949"},"modified":"2025-01-18T23:40:50","modified_gmt":"2025-01-18T15:40:50","slug":"clover-biopharmaceuticals-secures-exclusive-deal-for-adimflu-s-distribution-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=21949","title":{"rendered":"Clover Biopharmaceuticals Secures Exclusive Deal for AdimFlu-S Distribution in China"},"content":{"rendered":"\n<p>China-based Clover Biopharmaceuticals, Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/2197:HKG\">HKG: 2197<\/a>) has announced an exclusive agreement with Adimmune Corporation for the distribution of AdimFlu-S (QIS) in mainland China. AdimFlu-S (QIS) is the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older in China. The agreement also grants Clover rights to commercialize AdimFlu-S (QIS) in Bangladesh, Brazil, and the Philippines, subject to regulatory approvals, and opens the door for potential collaboration on the development of additional vaccine candidates, including next-generation influenza vaccines.<\/p>\n\n\n\n<p><strong>Manufacturing and Regulatory Compliance<\/strong><br>Adimmune will manufacture AdimFlu-S (QIS) at its facility, which has been certified for good manufacturing practices (GMP) by the European Medicines Agency and the US FDA, among other regulatory bodies. This ensures the vaccine meets the highest standards of quality and safety.<\/p>\n\n\n\n<p><strong>Vaccine Efficacy and Approval<\/strong><br>AdimFlu-S (QIS) is a quadrivalent split inactivated vaccine designed to prevent influenza. As a quadrivalent vaccine, it contains hemagglutinin from four influenza virus strains (two A and two B), which enhances its effectiveness regardless of which influenza B strain becomes seasonally prevalent, compared to trivalent options. The vaccine was approved by the China National Medical Products Administration in January 2022 for individuals aged three years and older.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced an exclusive agreement with Adimmune Corporation for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[651,697,1123,12],"class_list":["post-21949","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-clover-biopharmaceuticals","tag-gmp-gcp-gsp","tag-hkg-2197","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Clover Biopharmaceuticals Secures Exclusive Deal for AdimFlu-S Distribution in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced an exclusive agreement with Adimmune Corporation for the distribution of AdimFlu-S (QIS) in mainland China. AdimFlu-S (QIS) is the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older in China. The agreement also grants Clover rights to commercialize AdimFlu-S (QIS) in Bangladesh, Brazil, and the Philippines, subject to regulatory approvals, and opens the door for potential collaboration on the development of additional vaccine candidates, including next-generation influenza vaccines.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=21949\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clover Biopharmaceuticals Secures Exclusive Deal for AdimFlu-S Distribution in China\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=21949\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-20T15:38:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-18T15:40:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21949#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21949\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Clover Biopharmaceuticals Secures Exclusive Deal for AdimFlu-S Distribution in China\",\"datePublished\":\"2023-02-20T15:38:00+00:00\",\"dateModified\":\"2025-01-18T15:40:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21949\"},\"wordCount\":212,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clover Biopharmaceuticals\",\"GMP \\\/ GCP \\\/ GSP\",\"HKG: 2197\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21949#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21949\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=21949\",\"name\":\"Clover Biopharmaceuticals Secures Exclusive Deal for AdimFlu-S Distribution in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-02-20T15:38:00+00:00\",\"dateModified\":\"2025-01-18T15:40:50+00:00\",\"description\":\"China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced an exclusive agreement with Adimmune Corporation for the distribution of AdimFlu-S (QIS) in mainland China. AdimFlu-S (QIS) is the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older in China. The agreement also grants Clover rights to commercialize AdimFlu-S (QIS) in Bangladesh, Brazil, and the Philippines, subject to regulatory approvals, and opens the door for potential collaboration on the development of additional vaccine candidates, including next-generation influenza vaccines.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21949#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21949\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21949#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clover Biopharmaceuticals Secures Exclusive Deal for AdimFlu-S Distribution in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Clover Biopharmaceuticals Secures Exclusive Deal for AdimFlu-S Distribution in China - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced an exclusive agreement with Adimmune Corporation for the distribution of AdimFlu-S (QIS) in mainland China. AdimFlu-S (QIS) is the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older in China. The agreement also grants Clover rights to commercialize AdimFlu-S (QIS) in Bangladesh, Brazil, and the Philippines, subject to regulatory approvals, and opens the door for potential collaboration on the development of additional vaccine candidates, including next-generation influenza vaccines.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=21949","og_locale":"en_US","og_type":"article","og_title":"Clover Biopharmaceuticals Secures Exclusive Deal for AdimFlu-S Distribution in China","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=21949","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-02-20T15:38:00+00:00","article_modified_time":"2025-01-18T15:40:50+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=21949#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=21949"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Clover Biopharmaceuticals Secures Exclusive Deal for AdimFlu-S Distribution in China","datePublished":"2023-02-20T15:38:00+00:00","dateModified":"2025-01-18T15:40:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=21949"},"wordCount":212,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clover Biopharmaceuticals","GMP \/ GCP \/ GSP","HKG: 2197","Vaccine"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=21949#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=21949","url":"https:\/\/flcube.com\/?p=21949","name":"Clover Biopharmaceuticals Secures Exclusive Deal for AdimFlu-S Distribution in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-02-20T15:38:00+00:00","dateModified":"2025-01-18T15:40:50+00:00","description":"China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced an exclusive agreement with Adimmune Corporation for the distribution of AdimFlu-S (QIS) in mainland China. AdimFlu-S (QIS) is the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older in China. The agreement also grants Clover rights to commercialize AdimFlu-S (QIS) in Bangladesh, Brazil, and the Philippines, subject to regulatory approvals, and opens the door for potential collaboration on the development of additional vaccine candidates, including next-generation influenza vaccines.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=21949#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=21949"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=21949#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Clover Biopharmaceuticals Secures Exclusive Deal for AdimFlu-S Distribution in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21949","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21949"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21949\/revisions"}],"predecessor-version":[{"id":21950,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21949\/revisions\/21950"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21949"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21949"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21949"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}